A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer

被引:12
作者
Fiedler, W
Tchen, N
Bloch, J
Fargeot, P
Sorio, R
Vermorken, JB
Collette, L
Lacombe, D
Twelves, C
机构
[1] Univ Hamburg, Hosp Eppendorf, Dept Med 2, D-20251 Hamburg, Germany
[2] Inst Bergonie, Reg Canc Ctr, Bordeaux, France
[3] CHU Pitie Salpetriere, Dept Oncol, Paris, France
[4] Ctr Georges Francois Leclerc, Dept Oncol, Dijon, France
[5] Ctr Riferimento Oncol, Div Med Oncol 2, I-33081 Aviano, Italy
[6] Univ Ziekenhuis Antwerpen, Dept Med Oncol, Edegem, Belgium
[7] EORTC, New Drug Dev Programme, Data Ctr, Brussels, Belgium
[8] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
关键词
hormone -refractory prostate cancer; PSA; sabarubicin; MEN-10755; phase II;
D O I
10.1016/j.ejca.2005.07.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sabarubicin (MEN-10755), a new synthetic anthracycline analogue, was evaluated for safety and efficacy in a multicentre phase II study in patients with advanced hormone refractory prostate cancer (HRPC). Thirty seven patients were included, of which 34 were evaluable for PSA response according to Bubley's criteria. Sabarubicin was administered as a short (30 min) intravenous infusion at a dose of 80 Mg/m(2) every 3 weeks. The main toxicity consisted of grade 3/4 neutropenia in 24 patients (64.9%), with grade 3/4 febrile neutropenia occurring in one patient only. Grade 3/4 cardiotoxicity was observed in 4 patients including one ineligible. Other toxicities were mild. Nine patients achieved a PSA response (26.5%), 10 patients had stable disease (29.4%) and 14 patients disease progression (41.2%). One patient (2.9%) had a PSA response that was not confirmed by repeat PSA testing. The objective response rate according to RECIST criteria was 6.7% in 15 patients with measurable disease. The median duration of PSA responses was relatively long 7.1 months (95% CI 4.9-20.7) as was the median time to treatment progression in patients with stable disease. The median overall survival was 18.7 months (95% CI 9.1-N), comparable to results recently observed in taxotere-containing regimens. To confirm and extend these results, further testing of sabarubicin in larger trials is warranted. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:200 / 204
页数:5
相关论文
共 14 条
  • [1] Beedassy A, 1999, SEMIN ONCOL, V26, P428
  • [2] Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours
    Bos, AME
    de Vries, EGE
    Dombernovsky, P
    Aamdal, S
    Uges, DRA
    Schrijvers, D
    Wanders, J
    Roelvink, MWJ
    Hanauske, AR
    Bortini, S
    Capriati, A
    Crea, AEG
    Vermorken, JB
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (05) : 361 - 369
  • [3] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
    Bubley, GJ
    Carducci, M
    Dahut, W
    Dawson, N
    Daliani, D
    Eisenberger, M
    Figg, WD
    Freidlin, B
    Halabi, S
    Hudes, G
    Hussain, M
    Kaplan, R
    Myers, C
    Oh, W
    Petrylak, DP
    Reed, E
    Roth, B
    Sartor, O
    Scher, H
    Simons, J
    Sinibaldi, V
    Small, EJ
    Smith, MR
    Trump, DL
    Vollmer, R
    Wilding, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3461 - 3467
  • [4] A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA
    CRAWFORD, ED
    EISENBERGER, MA
    MCLEOD, DG
    SPAULDING, JT
    BENSON, R
    DORR, FA
    BLUMENSTEIN, BA
    DAVIS, MA
    GOODMAN, PJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) : 419 - 424
  • [5] Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
    Kantoff, PW
    Halabi, S
    Conaway, M
    Picus, J
    Kirshner, J
    Hars, V
    Trump, D
    Winer, EP
    Vogelzang, NJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2506 - 2513
  • [6] Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue
    Minotti, G
    Parlani, M
    Salvatorelli, E
    Menna, P
    Cipollone, A
    Animati, F
    Maggi, CA
    Manzini, S
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (06) : 1271 - 1278
  • [7] Anthracycline metabolism and toxicity in human myocardium: Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite
    Minotti, G
    Licata, S
    Saponiero, A
    Menna, P
    Calafiore, AM
    Di Giammarco, G
    Liberi, G
    Animati, F
    Cipollone, A
    Manzini, S
    Maggi, CA
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2000, 13 (12) : 1336 - 1341
  • [8] Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Petrylak, DP
    Tangen, CM
    Hussain, MHA
    Lara, PN,J
    Jones, JA
    Taplin, ME
    Burch, PA
    Berry, D
    Moinpour, C
    Kohli, M
    Benson, MC
    Small, EJ
    Raghavan, D
    Crawford, ED
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) : 1513 - 1520
  • [9] Pratesi G, 1998, CLIN CANCER RES, V4, P2833
  • [10] Phase I study of men-10755 in patients with a solid tumor as a short i.v. infusion given once every 3 weeks
    Roelvink, M
    Aamdal, S
    Dombernowsky, P
    Wanders, J
    Peters, S
    Bortini, S
    Crea, A
    Animati, A
    Hanauske, AR
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S289 - S289